AFT Pharmaceuticals’ shares fall as drug fails FDA threshold

AFT Pharmaceuticals’ shares fall as drug fails FDA threshold
AFT Pharmaceuticals managing director Hartley Atkinson still believes Pascomer shows promise. (Image: AFT Pharmaceuticals)
Riley Kennedy
AFT Pharmaceuticals’ shares have fallen this morning after the company said a drug it is developing to treat facial angiofibromas (FA) had failed to reach the threshold for US Food and Drug Administration (FDA) registration.The company’s shares declined 3.3% to $3.80 in morning trading, after the pharmaceutical company released the findings of its study of its orphan drug Pascomer, which it said found “statistically significant” benefits. However, it did not reach the threshold on the IGA scale – a five-point...

More Markets

SkyCity claims it is entitled to $330m in damages from Fletcher Building
Markets

SkyCity claims it is entitled to $330m in damages from Fletcher Building

The original delivery date of the International Convention Centre was January 2019. 

10 NZ firms could get slice of $200m Fisher KiwiSaver cash
Markets

10 NZ firms could get slice of $200m Fisher KiwiSaver cash

Private equity investing will benefit both KiwiSavers and business, fund manager says.